Jilin Aodong Pharmaceutical Group Co.Ltd(000623) (SZ Jilin Aodong Pharmaceutical Group Co.Ltd(000623) , closing price: RMB 16.83) the annual performance report released on April 16 said that the operating revenue in 2021 was about RMB 2.304 billion, an increase of 2.31% year-on-year; The net profit attributable to shareholders of listed companies was about 1.781 billion yuan, an increase of 4.19% year-on-year; The basic earnings per share was 1.5626 yuan, a year-on-year increase of 5.92%. It is proposed to pay a cash dividend of 3 yuan (including tax) for every 10 shares, no bonus shares and no increase.
From January to December 2021, Jilin Aodong Pharmaceutical Group Co.Ltd(000623) the operating revenue composition is as follows: pharmaceutical industry accounts for 78.69%, chain drugstore wholesale and retail accounts for 10.79%, food accounts for 6.75%, and other industries account for 1.99%.
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) ‘s chairman is Li Xiulin, male, 69 years old, with a bachelor’s degree; The general manager is Guo Shuqin, female, 59 years old, with a college education background.
